We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
-11.05%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.3B
AUM Growth
-$460M
(-17%)
Cap. Flow
-$148M
Cap. Flow
% of AUM
-6.44%
Top 10 Holdings %
Top 10 Hldgs %
58.87%
Holding
47
New
10
Increased
12
Reduced
5
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SEM
Select Medical
SEM
|
+$71.5M |
| 2 |
Tenet Healthcare
THC
|
+$67.9M |
| 3 |
Dentsply Sirona
XRAY
|
+$50.5M |
| 4 |
Sarepta Therapeutics
SRPT
|
+$34.9M |
| 5 |
Myriad Genetics
MYGN
|
+$31.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$149M |
| 2 |
Merck
MRK
|
+$123M |
| 3 |
Universal Health Services
UHS
|
+$107M |
| 4 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
+$85.8M |
| 5 |
Medtronic
MDT
|
+$55.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.09% |
| 2 | Technology | 2.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Viatris
VTRS
$20.8B
| $241M | 10.45% |
23,000,000
| – | – |
|
2
Sanofi
SNY
$107B
| $200M | 8.68% |
4,000,000
| – | – |
|
3
Zimmer Biomet
ZBH
$18.8B
| $142M | 6.15% |
1,350,000
| – | – |
|
|
4
Sarepta Therapeutics
SRPT
$1.64B
| $139M | 6.02% |
1,850,000
+475,000
| +35% | +$34.9M |
|
5
BioMarin Pharmaceuticals
BMRN
$11.9B
| $124M | 5.39% |
1,500,000
+200,000
| +15% | +$15.9M |
|
6
Perrigo
PRGO
$1.44B
| $112M | 4.84% |
2,750,000
+250,000
| +10% | +$9.29M |
|
|
WBA
7
DELISTED
Walgreens Boots Alliance
WBA
| $107M | 4.65% |
2,825,000
+425,000
| +18% | +$18.3M |
|
8
Ionis Pharmaceuticals
IONS
$8.93B
| $100M | 4.34% |
2,700,000
-300,000
| -10% | -$11.3M |
|
9
PTC Therapeutics
PTCT
$6.18B
| $98.1M | 4.26% |
2,450,000
+700,000
| +40% | +$24.5M |
|
|
SEM
10
DELISTED
Select Medical
SEM
| $94.5M | 4.1% |
7,424,000
+5,568,000
| +300% | +$71.5M |
|
11
Incyte
INCY
$25.8B
| $91.2M | 3.96% |
1,200,000
-150,000
| -11% | -$11.4M |
|
|
12
Myriad Genetics
MYGN
$476M
| $90.8M | 3.94% |
5,000,000
+1,500,000
| +43% | +$31.1M |
|
|
13
Tenet Healthcare
THC
$22.2B
| $86.7M | 3.76% |
1,650,000
+975,000
| +144% | +$67.9M |
|
|
14
Universal Health Services
UHS
$10.2B
| $75M | 3.26% |
745,000
-855,000
| -53% | -$107M |
|
15
Brookdale Senior Living
BKD
$3.55B
| $72.6M | 3.15% |
16,000,000
| – | – |
|
|
CHNG
16
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $53.6M | 2.33% |
2,325,000
-3,675,000
| -61% | -$85.8M |
|
|
RETA
17
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $45.6M | 1.98% |
1,500,000
| – | – |
|
|
18
Dentsply Sirona
XRAY
$2.84B
| $44.7M | 1.94% |
+1,250,000
| New | +$50.5M |
|
|
MRTX
19
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $43.6M | 1.89% |
650,000
-550,000
| -46% | -$35M |
|
20
Exelixis
EXEL
$13.9B
| $34.4M | 1.49% |
1,650,000
+1,350,000
| +450% | +$27.8M |
|
|
ZIMV
21
DELISTED
ZimVie
ZIMV
| $32M | 1.39% |
2,000,000
| – | – |
|
22
Evolent Health
EVH
$371M
| $30.7M | 1.33% |
1,000,000
+814,600
| +439% | +$23.7M |
|
23
Biogen
BIIB
$30.9B
| $25.5M | 1.11% |
+125,000
| New | +$25.6M |
|
|
NUVA
24
DELISTED
NuVasive, Inc.
NUVA
| $24.6M | 1.07% |
500,000
| – | – |
|
25
Align Technology
ALGN
$12.9B
| $23.7M | 1.03% |
+100,000
| New | +$30.7M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, Camber Capital Management held 47 positions worth $2.3B, down 17% from $2.76B the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Camber Capital Management withdrew a net $148M in Q2 2022, closing 7 positions and reducing 5 holdings. Its most notable exit was Gilead Sciences, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier, followed by Technology.
Against the trend, Camber Capital Management opened a new position in Dentsply Sirona worth $44.7M.
- Camber Capital Management's largest Q2 2022 buy was Dentsply Sirona: 1,250,000 shares worth $44.7M.
- Camber Capital Management added most to Select Medical in Q2 2022, an estimated $71.5M increase.
- Camber Capital Management's biggest Q2 2022 reduction was Universal Health Services, cutting an estimated $107M.
- Camber Capital Management fully exited Gilead Sciences in Q2 2022, selling an estimated $149M.
- Camber Capital Management's ten largest holdings make up 59% of its $2.3B portfolio in Q2 2022.
- Camber Capital Management opened 10 new positions and closed 7 in Q2 2022.
- Camber Capital Management's portfolio value fell 17% quarter-over-quarter to $2.3B.
Based on Camber Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.